Revision as of 19:34, 23 October 2007 editTruther truther (talk | contribs)430 editsNo edit summary← Previous edit | Revision as of 19:39, 23 October 2007 edit undoTruther truther (talk | contribs)430 editsNo edit summaryNext edit → | ||
Line 13: | Line 13: | ||
==Sunitinib Development Controversy== | ==Sunitinib Development Controversy== | ||
Joseph Schlessinger founded Sugen and claimed to have come up with the idea of combining an antibody with a chemotherapy agent. Joseph Schlessinger's colleagues at the Weizmann Institute in Isreal claimed to have come up with this concept first and the case was taken to a district court in the US. Joseph Schlessinger gave testimony in court that stated he District court Judge accused Joseph Schlessinger of purging himself | Joseph Schlessinger founded Sugen and claimed to have come up with the idea of combining an antibody with a chemotherapy agent. Joseph Schlessinger's colleagues at the Weizmann Institute in Isreal claimed to have come up with this concept first and the case was taken to a district court in the US. Joseph Schlessinger gave testimony in court that stated he District court Judge accused Joseph Schlessinger of purging himself. In a Money Magazine article Judge Buchwald described Joseph Schlessinger's testimony as "dismissed his testimony as 'not credible,' 'contorted,' 'incredible' and 'wholly unsubstantiated by any contemporaneous records.'" <ref></ref> Joseph Schlessinger has not made any written response to these alligations. | ||
==Yale University== | ==Yale University== |
Revision as of 19:39, 23 October 2007
Joseph Schlessinger, Ph.D. is Chair of the Pharmacology Department at Yale University in New Haven, Connecticut. His area of research is Tyrosine phosphorylation which potentially plays a role in the treatment of several different types of cancer.
Education
Joseph Schlessinger has been the William H. Prusoff Professor and Chairman of the Department of Pharmacology at Yale University School of Medicine since 2001. According to his website, prior to coming to Yale, Joseph Schlessinger was the Director of the Skirball Institute for Biomolecular Medicine at New York University (NYU) Medical Center from 1998–2001 and the Milton and Helen Kimmelman Professor and Chairman of the Department of Pharmacology at NYU Medical School from 1990–2001. He was a member of the faculty of the Weizmann Institute from 1978–1991.
Publications
According to PubMed, Joseph Schlessinger has authored over 400 scientific review articles and original publications in the area of pharmacology.
Personal life
Joseph Schlessinger is married to Irit Lax who he appointed as an assistant professor in his Department at shortly after becoming chairman. It is unclear what degree she holds or the focus of research, but PubMed shows that she and Joseph Schlessinger coauthored many publications together.
Sunitinib Development Controversy
Joseph Schlessinger founded Sugen and claimed to have come up with the idea of combining an antibody with a chemotherapy agent. Joseph Schlessinger's colleagues at the Weizmann Institute in Isreal claimed to have come up with this concept first and the case was taken to a district court in the US. Joseph Schlessinger gave testimony in court that stated he District court Judge accused Joseph Schlessinger of purging himself. In a Money Magazine article Judge Buchwald described Joseph Schlessinger's testimony as "dismissed his testimony as 'not credible,' 'contorted,' 'incredible' and 'wholly unsubstantiated by any contemporaneous records.'" Joseph Schlessinger has not made any written response to these alligations.
Yale University
Other
References
- Schlessinger Lab: Biography
- "Schlessinger Lab: Biography". Retrieved 2007-10-23.
- Bruised ImClone takes another hit
- Yale School of Medicine appoints Joseph Schlessinger, formerly of NYU, Pharmacology Chair., M2 Presswire, 05-JUN-01.
- YALE RESEARCHER SHARES $1 MILLION PRIZE
- http://www.med.yale.edu/pharm/chairman/biography.htm
This biographical article about a scientist is a stub. You can help Misplaced Pages by expanding it. |